<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21503">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656512</url>
  </required_header>
  <id_info>
    <org_study_id>CCHE-ALL002</org_study_id>
    <nct_id>NCT01656512</nct_id>
  </id_info>
  <brief_title>Zometa Study in Pediatric Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Analysis of Outcome of Bisphosphonate Use in Children With ALL- &quot;Case Controlled Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer Hospital Egypt 57357</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Cancer Hospital Egypt 57357</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts
      for one fourth of all  childhood cancers &amp; 74 % of childhood leukemia. Based upon drug
      registry data, children prescribed more than three courses of systemic glucocorticoids
      yearly faced a 20% increase in age-adjusted fracture rates. Rapid recovery occurred once
      glucocorticoids were discontinued, and fracture rates returned to expected for age by 1 year
      after treatment (Journal Of Clinical  Endocrinology &amp; Metabolism 2009). The investigators
      will study the role of bisphosphonates in the prevention of secondary osteoporosis in
      children &amp; adolescents treated for ALL  in  the Children's Cancer Hospital -Egypt.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Measure the change in the Bone densitometry due to secondary osteoporosis</measure>
    <time_frame>1- At baseline ( not more than 48 hours of start of therapy with steroids)   2- At  week 48       3- At end of treatment ( week 120 for girls )   &amp; ( week 146 for boys)         4-As required  clinically eg: fractures .</time_frame>
    <safety_issue>No</safety_issue>
    <description>we will do the following for evaluation :
Bone densitometry using Dual-energy x-ray absorptiometry (DXA) scan analyzed  using the Z-score. To  be done :
At baseline ( not more than 48 hours of start of therapy with steroids)
At  week 48
At end of treatment ( week 120 for girls )   &amp; ( week 146 for boys)
As required  clinically eg: fractures .
Magnetic resonance imaging of both hips &amp; knees will be done at reinduction I &amp; II  &amp; if symptomatic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- To assess the percentage change in lumbar spine BMD at wk 48 relative to baseline in both arms.</measure>
    <time_frame>week 48 continuation phase</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Arm ( A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm ( A) : patients  will receive calcium &amp; vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic   acid ) every 3 months in the dose of</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolendronic   acid</intervention_name>
    <description>patients will receive calcium &amp; vitamin D daily in addition to bisphosphonates (zolendronic   acid ) every 3 months in the dose of
Initial dose: (0.025) mg /kg
Subsequent doses ( 0.05) mg /kg.
Maximum dose of 4 mg.</description>
    <arm_group_label>Arm (B)</arm_group_label>
    <other_name>bisphosphonates</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium &amp; vitamin D</intervention_name>
    <description>patients  will receive calcium &amp; vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit</description>
    <arm_group_label>Arm ( A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 5 &amp;  below 18 years at the time of diagnosis.

          -  Newly diagnosed ALL patients.

          -  Not previously treated, previous steroid intake not more than 72 hours.

          -  Treated according to St Judy study XV protocol.

        Exclusion Criteria:

          -  Previous steroid intake more than 72 hours.

          -  Less than 5 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shimaa Samir, MBBCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Cancer Hospital Egypt 57357</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimaa Samir, MBBCH</last_name>
    <email>dr_shaimaasamir@yahoo.com,</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Cancer Hospital Egypt 57357</name>
      <address>
        <city>Cairo</city>
        <zip>11441</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wafaa Rashed, Pharm B</last_name>
      <phone>+225351500</phone>
      <phone_ext>7209</phone_ext>
      <email>waffa.rashed@57357.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 1, 2012</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>Osteoporosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
